267 related articles for article (PubMed ID: 24080149)
1. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
[TBL] [Abstract][Full Text] [Related]
2. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Sawada T; Shinke T; Shite J; Honjo T; Haraguchi Y; Nishio R; Shinohara M; Toh R; Ishida T; Kawamori H; Kozuki A; Inoue T; Hariki H; Hirata K
Circ J; 2011; 75(1):99-105. PubMed ID: 21099121
[TBL] [Abstract][Full Text] [Related]
3. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytochrome P450 2C19 loss-of-function polymorphism on intra-stent thrombi and lesion outcome after everolimus-eluting stent implantation compared to that after first-generation drug-eluting stent implantation.
Konishi A; Shinke T; Otake H; Nishio R; Sawada T; Takaya T; Nakagawa M; Osue T; Taniguchi Y; Iwasaki M; Kinutani H; Masaru K; Takahashi H; Terashita D; Shite J; Hirata K
Int J Cardiol; 2015 Jan; 179():476-83. PubMed ID: 25465810
[TBL] [Abstract][Full Text] [Related]
5. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
[TBL] [Abstract][Full Text] [Related]
6. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.
Park KW; Park JJ; Lee SP; Oh IY; Suh JW; Yang HM; Lee HY; Kang HJ; Cho YS; Koo BK; Youn TJ; Chae IH; Choi DJ; Oh BH; Park YB; Kim HS
Heart; 2011 Apr; 97(8):641-7. PubMed ID: 21345843
[TBL] [Abstract][Full Text] [Related]
7. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus assessed by follow-up optical coherence tomography in Chinese patients receiving clopidogrel.
Li S; Shi Y; Wang H; Zhang W; Liu J
J Thromb Thrombolysis; 2015 Jul; 40(1):88-96. PubMed ID: 25800884
[TBL] [Abstract][Full Text] [Related]
8. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
9. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
10. Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
Park J; Shin DH; Kim BK; Her AY; Kim YH; Choi HH; Kim JS; Ko YG; Choi D; Jang Y; Hong MK
Eur Heart J Cardiovasc Imaging; 2013 Dec; 14(12):1181-6. PubMed ID: 23657678
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
Choi IJ; Koh YS; Park MW; Her SH; Choi YS; Park CS; Park HJ; Kim PJ; Chung WS; Kim HS; Shin JG; Seung KB; Chang K
Medicine (Baltimore); 2016 Jun; 95(26):e4049. PubMed ID: 27368038
[TBL] [Abstract][Full Text] [Related]
12. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D
Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387
[TBL] [Abstract][Full Text] [Related]
13. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.
Oh IY; Park KW; Kang SH; Park JJ; Na SH; Kang HJ; Koo BK; Jeong YH; Hwang JY; Kwak CH; Park Y; Hwang SJ; Ko YG; Shin DJ; Jang Y; Kim HS
Heart; 2012 Jan; 98(2):139-44. PubMed ID: 21700758
[TBL] [Abstract][Full Text] [Related]
14. Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel.
Nishio R; Shinke T; Otake H; Sawada T; Haraguchi Y; Shinohara M; Toh R; Ishida T; Nakagawa M; Nagoshi R; Kozuki A; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Shite J; Hirata K
Circ J; 2012; 76(10):2348-55. PubMed ID: 22785462
[TBL] [Abstract][Full Text] [Related]
15. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.
Zhang HZ; Kim MH; Han JY; Jeong YH
Platelets; 2014; 25(4):285-91. PubMed ID: 23971745
[TBL] [Abstract][Full Text] [Related]
16. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
[TBL] [Abstract][Full Text] [Related]
19. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
20. The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Xie C; Ding X; Gao J; Wang H; Hang Y; Zhang H; Zhang J; Jiang B; Miao L
Pharmacogenet Genomics; 2014 Apr; 24(4):204-10. PubMed ID: 24535487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
